PUBLISHER: DelveInsight | PRODUCT CODE: 1159551
PUBLISHER: DelveInsight | PRODUCT CODE: 1159551
DelveInsight's , "Genital Herpes - Pipeline Insight, 2022," report provides comprehensive insights about 26+ companies and 28+ pipeline drugs in Genital Herpes pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Genital Herpes Understanding
Genital Herpes: Overview
Herpes genitalis is among the most common sexually transmitted infections. It is caused by the herpes simplex virus type 2 (HSV-2) and also, increasingly, the herpes simplex virus type 1 (HSV-1). Both organisms are enveloped DNA viruses that are sensitive to disinfectants and environmental factors 1. Due to marked genetic homology between HSV-1 and HSV-2 numerous biological similarities and antigenic cross-reactions between the viruses exist. Type-specific epitopes include the viral glycoproteins (g) gG (HSV-1 and HSV-2) and gC (HSV-1). The primary mode of transmission of both HSV-1 and HSV-2 is through direct contact. Initial infection with HSV-1 occurs most often during childhood following the disappearance of maternal antibodies during the first year of life.
"Genital Herpes - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Genital Herpes pipeline landscape is provided which includes the disease overview and Genital Herpes treatment guidelines. The assessment part of the report embraces, in depth Genital Herpes commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
This segment of the Genital Herpes report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Genital Herpes Emerging Drugs
Pritelivir is a highly potent inhibitor of HSV replication. It belongs to a new chemical class and acts via a novel mechanism of action (inhibition of the viral helicase-primase enzyme complex). In contrast to currently used nucleoside analogues, Pritelivir does not require activation by viral enzymes and can thus protect uninfected cells. Pritelivir is being developed for the treatment of acyclovir-resistant and dual-resistant (resistant to acyclovir and intolerant or resistant to foscarnet) infections in immune-compromised patients.
UB 621 is a novel, fully human monoclonal antibody that interferes with HSV infection by binding specifically to HSV envelope glycoprotein D (gD). It has been shown in vitro to block HSV infections of both wild type and acyclovir-resistant viral strains with over hundreds-fold higher potency. Pre-clinical and early clinical data show that UB-621 has the potential to suppress recurrence of genital herpes. The drug is in phase II stage of development for the treatment of Genital Herpes.
Further product details are provided in the report……..
Genital Herpes: Therapeutic Assessment
This segment of the report provides insights about the different Genital Herpes drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 26+ key companies which are developing the therapies for Genital Herpes. The companies which have their Genital Herpes drug candidates in the most advanced stage, i.e. Phase III include, AiCuris.
DelveInsight's report covers around 28+ products under different phases of clinical development like
Genital Herpes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Molecule Type
Products have been categorized under various Molecule types such as
Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Genital Herpes: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Genital Herpes therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Genital Herpes drugs.
Key Questions
Current Treatment Scenario and Emerging Therapies:
Key Players
Key Products
Introduction
Executive Summary
Genital Herpes : Overview
Pipeline Therapeutics
Therapeutic Assessment
Genital Herpes - DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
Pritelivir: AiCuris
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
UB 621: United BioPharma
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
HSV-2 DNA Vaccine: Admedus Immunotherapies
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
BNT 163: BioNTech SE
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Genital Herpes Key Companies
Genital Herpes Key Products
Genital Herpes -Unmet Needs
Genital Herpes -Market Drivers and Barriers
Genital Herpes -Future Perspectives and Conclusion
Genital Herpes Analyst Views
Genital Herpes Key Companies
Appendix